Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours by Strumberg, D et al.
Phase I dose escalation study of telatinib (BAY 57-9352) in
patients with advanced solid tumours
D Strumberg*,1, B Schultheis
1, IA Adamietz
2, O Christensen
3, M Buechert
4, J Kraetzschmar
5, P Rajagopalan
3,
M Ludwig
5, A Frost
6, S Steinbild
6, ME Scheulen
7 and K Mross
6
1Department of Haematology and Medical Oncology, University of Bochum (Marien Hospital, Herne), Herne, Germany;
2Department of Radiotherapy,
University of Bochum (Marien Hospital, Herne), Herne, Germany;
3Bayer Pharmaceuticals Inc., Montville, NJ, USA;
4Magnetic Resonance Development
and Application Centre, University Hospital, Freiburg, Germany;
5Bayer Schering Pharma, Wuppertal, Germany;
6Tumour Biology Centre at the Albert-
Ludwigs-University, Freiburg, Germany;
7Department of Internal Medicine and Medical Oncology, West German Cancer Centre, University of Essen,
Germany
Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and
3 (VEGFR-2/-3) and platelet-derived growth factor receptor b tyrosine kinases. In this multicentre phase I dose escalation study,
71 patients with refractory solid tumours were enroled into 14 days on/7 days off (noncontinuous dosing) or continuous dosing
groups to receive telatinib two times daily (BID). Hypertension (23%) and diarrhoea (7%) were the most frequent study drug-related
adverse events of CTC grade 3. The maximum-tolerated dose was not reached up to a dose of 1500mg BID continuous dosing.
Telatinib was rapidly absorbed with median tmax of 3 hours or less. Geometric mean Cmax and AUC0 12 increased in a less than dose-
proportional manner and plateaued in the 900–1500mg BID dose range. Two renal cell carcinoma patients reached a partial
response. Tumour blood flow measured by contrast-enhanced magnetic resonance imaging and sVEGFR-2 plasma levels decreased
with increasing AUC0 12 of telatinib. Telatinib is safe and well tolerated up to a dose of 1500mg BID continuous dosing. Based on
pharmacokinetic and pharmacodynamic criteria, 900mg telatinib BID continuously administered was selected as the recommended
phase II dose.
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Telatinib (BAY 57-9352) is an orally available, potent, small-
molecule inhibitor of vascular endothelial growth factor (VEGF)
receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor
(PDGF) receptor b (PDGFR-b) tyrosine kinases.
The growth of solid tumours is accompanied by angiogenesis
(Algire et al, 1945) and the development of an effective vascular
network is required for the tumours to grow beyond 1ml in volume
(Folkman, 1990). Anti-angiogenesis is an interesting strategy for
the treatment of cancer (Folkman, 1971). VEGF and its receptor,
VEGFR-2, which is expressed on activated endothelial cells
associated with growing solid tumours, are required for the
angiogenic process (Folkman, 2002; Pisacane and Risio, 2005).
Continued signal transduction through the VEGF/VEGFR-2 path-
way is a primary stimulus for initiation and maintenance of
tumour angiogenesis (Ellis, 2004). Blocking the interaction of
VEGF with the VEGFR-2 receptor or inhibiting the tyrosine kinase
activity of the VEGFR-2 receptor blocks both angiogenesis and
tumour growth in in vivo models. Complete suppression of tumour
growth has been demonstrated using dominant-negative VEGF
receptors (Zhang et al, 1995; Millauer et al, 1996; Goldman et al,
1998) and blocking antibodies (Kim et al, 1993; Asano et al, 1995;
Warren et al, 1995; Melnyk et al, 1996; Yuan et al, 1996; Borgstrom
et al, 1998) as well as small-molecule inhibitors of VEGFR-2 kinase
(Wood et al, 2000; Wedge et al, 2002) as single-agent therapies in
model systems. Overexpression of VEGF is common in solid
tumours and associated with poorer prognosis (Dosquet et al,
1997; Raben and Helfrich, 2004; Giatromanolaki et al, 2006).
Telatinib is a potent inhibitor of VEGFR-2 and PDGFR-b tyrosine
kinase activity measured in a biochemical assay. These two
receptors play key roles in the angiogenic process involving the
stimulation of endothelial cells and PDGFR-expressing pericytes.
Telatinib inhibited VEGFR-2 autophosphorylation in a whole-cell
assay of receptor autophosphorylation in vitro, VEGF-dependent
proliferation of human umbilical vein endothelial cells in vitro,a n d
PDGF-stimulated growth of human aortic smooth muscle cells.
Telatinib demonstrated potent, dose-dependent reduction in
tumour growth in vivo in a variety of models including MDA-MB-
231 breast carcinoma, Colo-205 colon carcinoma, DLD-1 colon
carcinoma and H460 non-small cell lung carcinoma. Toxicological
studies supported the start of a clinical study in cancer patients at a
dose level of 10mg (once daily (OD)) of telatinib. Received 15 September 2008; accepted 16 September 2008
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main target of metabolic degradation. The in vitro investigations
using human microsomes, hepatocytes or single cytochrome
P450 (CYP) isoforms revealed that there is no or only a very low
risk of drug–drug interactions. Telatinib was metabolised by
various CYP isoforms. There was no critical involvement of
polymorphic CYP isoforms in the biotransformation. Telatinib
exhibited neither an inhibitory nor an inductive potential on major
human CYP isoforms at therapeutically relevant concentrations.
Drug–drug interactions are also unlikely to occur due to
displacement from plasma protein-binding sites or modulation
of p-glycoprotein transporter activity based on the results of
in vitro studies.
This phase I clinical study had the objective to determine the
dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD)
and pharmacokinetics of oral telatinib. Preliminary antitumour
activity, interaction with a variety of biomarkers including
VEGFR-2 and dynamic contrast-enhanced magnetic resonance
imaging (DCE-MRI) were evaluated.
PATIENTS AND METHODS
Patient selection
Eligible patients were X18 years of age, with a life expectancy of at
least 12 weeks, and a solid tumour that was refractory to standard
treatment or without standard therapy options. Patients had to
have Eastern Cooperative Oncology Group (ECOG) performance
status of 0–1. All patients had evaluable disease according to the
Response Evaluation Criteria in Solid Tumours (RECIST) criteria.
Patients might have had any number of prior systemic therapy,
radiotherapy or surgery, but therapies had to be discontinued at
least 4 weeks before study entry (6 weeks in case of mitomycin C
and nitrosoureas).
Other eligibility criteria included the following: (1) adequate
haematopoietic (absolute neutrophil count (ANC) X1.5 10
9
l
 1; platelet count X150 10
9l
 1 and haemoglobin X9.0gdl
 1),
hepatic (total bilirubin p1.5 times the upper limit of normal
(ULN); aspartate aminotransferase and alanine aminotransferase
p2.5 times ULN; prothrombin time and international normalised
ratio of partial thromboplastin time o1.5 times ULN unless on
therapeutic anticoagulants), and renal (serum creatinine p1.5
times ULN) functions; (2) no pregnancy and breast feeding; (3) no
clinically relevant co-morbidity such as cardiovascular diseases
and no clinically relevant co-medication; (4) no metastatic brain or
meningeal tumours, unless the patient was 46 months from
definitive therapy and had a negative imaging study within 4 weeks
of study entry.
All patients provided written informed consent in accor-
dance with federal and institutional guidelines before study
treatment.
Study design
This was a multicentre, open-label, non-controlled, phase I dose
escalation study to investigate the safety, pharmacokinetics and
pharmacodynamics of oral telatinib (BAY 57-9352). Administra-
tion of telatinib was continued until an unacceptable toxicity,
disease progression or death occurred or the consent was
withdrawn. At start of the study, only a solution formulation was
available. The formulation as tablet was introduced into the study
after first pharmacokinetic results became available. Based on
pharmacokinetic data, OD, two times daily (BID), and three times
daily schedules were evaluated. For the sake of clarity, the data
presented in this paper refer to the patients enroled into the BID 14
days on/7 days off (noncontinuous dosing) and continuous dosing
groups only.
Three patients were initially enroled at each dose level. If no
DLT had occurred at the end of the 3-week treatment cycle, three
patients were enroled at the next dose level. If any patient
experienced a DLT, three additional patients were enroled at that
dose level. If at least two out of six patients experienced a DLT,
dose escalation had to be stopped and that dose was to be declared
the toxic dose. The next lower dose level was defined as the MTD.
DLTs were defined as grade 3 or 4 non-haematological toxi-
cities, febrile neutropenia (ANC o0.5 10
9l
 1 and fever X38.51C),
grade 4 neutropenia lasting for at least 7 days, platelet count
o25 10
9l
 1 or grade 3 or 4 thrombocytopaenic bleeding, which
occurred during cycle 1. In the course of the study the protocol was
amended so that the onset of CTC grade 3 hypertension was only
considered to be a DLT if the hypertension turned out to be
refractory to standard antihypertensive treatment. The number of
patients enroled per dose level was extended to six patients for the
dose levels of 150mg BID or higher to get more reliable estimates
for telatinib pharmacokinetic parameters.
Adverse events were assessed at the end of each cycle and graded
according to the National Cancer Institute Common Toxicity
Criteria (NCI CTC), v2.0 (Trotti et al, 2000).
Patient evaluation
History, physical examinations, haematological and biochemical
laboratory evaluations were performed at screening, on days 1, 7
and 14 of cycle 1 and on day 1 of subsequent cycles. Baseline
objective tumour measurements were performed within 4 weeks
prior to study treatment. Lesions at all disease sites were
categorised as either measurable or nonmeasurable. Indicator
lesions were selected and monitored throughout the study by the
same assessor and using the same technique. Tumour response
was evaluated according to the RECIST (Therasse et al, 2000).
Pharmacokinetics
Patients with at least one valid pharmacokinetic profile were valid
for the pharmacokinetic analysis. Plasma samples were collected
at predose and 0.5, 1, 2, 3, 4, 6, 8, and 12h postdose on day 1 and
day 14 of cycle 1 and were analysed for BAY 57-9352 and its
demethylated metabolite M-2, BAY 60-8246, using a validated
LC-MS-MS analytical method.
Plasma pharmacokinetic parameters, area under the curve from
time 0–12h after dosing (AUC0 12), area under the curve from
time 0 to last data point (AUC0 tn), maximum plasma concentra-
tion (Cmax), and time to maximum plasma concentration (tmax)o f
telatinib and its metabolite (BAY 60-8246) as well as half-life of
telatinib were calculated by non-compartmental methods using
WinNonlin version 4.1.a (Pharsight Corporation). The linear-
logarithmic trapezoidal rule was used for calculating AUC.
Half-life was calculated by linear least squares regression
after logarithmic transformation of the terminal concentrations.
Pharmacokinetic parameters were analysed using descriptive
statistics.
Pharmacodynamics
The effects of telatinib treatment on the plasma concentrations
of sVEGFR-2, VEGF and bFGF were determined from blood
samples taken at baseline, on day 14 of cycles 1, 2, 4, 6, etc. and at
the final visit. Samples were analysed using the relevant
quantitative enzyme-linked immunosorbent assay (ELISA) (R&D
Systems Europe, Oxford, UK) according to the manufacturer’s
instructions. DCE-MRI was performed at baseline, on day 2 (only
cycle 1), and on day 14 of cycles 1–3 to assess tumour blood flow/
tumour vessel permeability in a subgroup of patients (Morgan
et al, 2003).
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Patient characteristics
A total of 71 patients (30 women, 41 men) with refractory
advanced solid tumours were enroled into the BID noncontinuous
and continuous treatment groups. Patients’ median (range) age
was 60 (31–82) years, median (range) weight 73.6 (39–113) kg.
Baseline ECOG performance status was 0 in 36 patients (51%), 1 in
32 patients (45%) and 2 in 2 patients (3%). For one patient, no
baseline ECOG performance status was documented. The main
tumour types were colorectal cancer (n¼25, 35%), renal cell
carcinoma (n¼12, 17%), hepatocellular carcinoma (n¼9, 13%),
non-small cell lung cancer and pancreatic cancer (both n¼4, 6%).
56 patients (79%) had prior systemic anticancer therapy, 63 (93%)
prior anticancer surgery, and 20 (28%) prior radiotherapy. All 71
patients were valid for safety and pharmacokinetic analyses.
Dose escalation and MTD
Dose escalation started with a single oral dose of 10mg telatinib.
The starting dose was based on nonclinical data. Based on the
pharmacokinetic results of the first three patients, which showed a
considerably lower than expected exposure, multiple dosing was
initiated at 20mg OD. Doses of 20–300mg telatinib OD were
administered for 14 days followed by 7 days off treatment. At doses
of 150 and 300mg OD, no further increase in exposure to telatinib
was achieved. As safety and tolerability remained good, BID dosing
was initiated at 75mg BID using the same noncontinuous regimen
of 14 days followed by 7 days off treatment. For the sake of clarity,
the data presented in this paper refer to the patients enroled in the
BID-dosing cohorts only. Up to 1500mg BID in the noncontinuous
regimen, only two patients experienced DLTs, that is, grade 3
hypertension, at doses of 300 and 1500mg BID, respectively. A
further dose escalation beyond the 1500mg BID dose level was not
feasible due to the number of tablets to be taken. As the MTD had
not been reached for the noncontinuous treatment, the continuous
BID dosing was initiated at 600mg BID. Dose escalation was
stopped at 1500mg BID continuous dosing without reaching the
MTD of telatinib.
The results of the BID noncontinuous and continuous dosing
groups are reported here. Telatinib was administered as solution
and 25mg mesylate tablet in the 75mg BID noncontinuous dosing
group, as solution, 25 and 150mg mesylate tablets, and 150mg
base tablet in the 150mg BID noncontinuous dosing group, as
25mg mesylate tablet in the 300mg BID noncontinuous dosing
group, and as 150mg tablet in all other groups. Table 1 shows an
overview about the dose escalation steps and the treatment
duration. Fifteen patients were enroled at the 150mg BID dose
level as the relative bioavailability for different tablet formulations
was evaluated at this dose level.
Safety
In total, 21% of all patients experienced at least one adverse event
assessed by the investigators as study drug-related with worst CTC
grade of 1–2 and 25% at least one study drug-related adverse event
with worst CTC grade 3 (Table 2). There were no study drug-
related adverse events of CTC grades 4 or 5 reported in this study.
The most common toxicity was hypertension in 4% of the
patients with worst CTC grade 1–2 and in another 23% of the
patients with worst CTC grade 3 (Table 2). Grade 3 hypertension
occurred in one-third to half of the patients in the 600–1500mg
noncontinuous dosing groups and the 900mg continuous dosing
group (Table 2). In the 1200mg continuous dosing group, more
than two-thirds of the patients experienced grade 3 hypertension.
In most cases hypertension was clinically well manageable with a
standard antihypertensive treatment. In three patients at dose
levels of 300mg BID, 1500mg BID noncontinuous dosing and
1200mg BID continuous dosing, hypertension resulted in dose
reduction and dose interruption, in one of them finally to
permanent discontinuation of study drug treatment.
Other common adverse events were gastrointestinal toxicities
such as anorexia and diarrhoea (Table 2). Diarrhoea led to dose
reduction or interruption in four patients at dose levels of 900mg
BID or higher, in one of them to permanent discontinuation. One
patient at the 1500mg BID continuous dosing level had a dose
interruption due to nausea and vomiting.
Serious study drug-related adverse events (adverse events
leading to hospitalisation or assessed by the investigator as
medically important) occurred in five patients: two patients had
diarrhoea (dose levels: 1500mg BID noncontinuous and 1200mg
BID continuous dosing), two patients had hypertension (dose
levels: 1500mg BID noncontinuous and 1200mg BID continuous
dosing), and one patient experienced a hand–foot skin reaction
and dehydration (dose level: 900mg BID continuous dosing).
Dose-limiting toxicities were reported for two patients (dose
levels: 300mg BID and 1500mg BID noncontinuous dosing). Both
had hypertension refractory to standard treatment leading to dose
reduction of telatinib. As at the highest dose level administered in
this study, 1500mg BID continuous dosing, no patient out of six
patients experienced dose-limiting toxicities within the first 21
days of treatment, the MTD was not reached in this study.
Pharmacokinetics
Day 14 steady-state geometric mean (percent coefficient of
variation) telatinib and BAY 60-8246 pharmacokinetic parameters
are shown in Table 3 and day 14 geometric mean telatinib plasma
concentration vs time profiles are shown in Figure 1. For the
150mg BID dose level, pharmacokinetic results were available
from different exploratory formulations. For this dose level, results
from only the 25mg telatinib mesylate tablet formulation are
shown in Table 3 and Figure 1.
Following oral administration, telatinib was rapidly absorbed
with median tmax of 3h or less in the 75mg BID to 1500mg BID
dose range. Geometric mean Cmax increased in a less than dose-
proportional manner in the dose range of 75mg BID to 300mg
BID. Geometric mean Cmax increased two-fold between the 300 and
600mg BID dose level and subsequently increased in a less than
dose-proportional manner up to 1500mg BID. Although a reason
for the two-fold increase in geometric mean Cmax is not known, it
is not attributable to the 150mg telatinib mesylate tablet
Table 1 Treatment summary by treatment group and dose level (all
patients, N¼71)
Treatment group N
Duration (medication days)
(median (range)
Noncontinuous dosing (14 days on/7 days off)
75mg BID 4 106 (35–182)
150mg BID 15
a 77 (5–633)
300mg BID 8 58.5 (14–287)
600mg BID 6 77.5 (35–525)
900mg BID 6 156.5 (55–497)
1500mg BID 6 58.5 (35–387)
Continuous dosing
600mg BID 7 35 (11–216)
900mg BID 6 120.5 (64–164)
1200mg BID 7 160 (14–178)
1500mg BID 6 83 (35–120)
BID¼two times daily.
aAt the 150mg BID dose level, the relative bioavailability of
different tablet formulations was assessed. Therefore the data from 15 patients were
pooled for this analysis.
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sTable 2 Incidence of patients (NX2( X3%)) with study drug-related adverse events with worst CTC grades 1–2 and incidence of patients with study
drug-related adverse events with worst CTC grade 3
a (N(%); all patients, N¼71)
NCI CTC category
Noncontinuous dosing (mg BID) Continuous dosing (mg BID)
Total
NCI CTC term
CTC grades 1–2
75–300
(N¼27)
600
(N¼6)
900
(N¼6)
1500
(N¼6)
600
(N¼7)
900
(N¼6)
1200
(N¼7)
1500
(N¼6) N¼71
Any category
Any event 2 (7) 2 (33) 3 (50) 2 (33) 1 (14) 2 (33) 1 (14) 2 (33) 15 (21)
Cardiovascular
Hypertension 1 (17) 1 (17) 1 (17) 3 (4)
Constitutional symptoms
Fatigue 2 (33) 2 (3)
Gastrointestinal
Anorexia 1 (4) 1 (17) 1 (17) 2 (33) 5 (7)
Diarrhoea, patients without colostomy 1 (17) 1 (14) 2 (33) 4 (6)
Flatulence 1 (14) 1 (17) 2 (3)
Nausea 1 (17) 1 (17) 1 (17) 3 (4)
Vomiting 1 (17) 1 (17) 2 (3)
Pulmonary
Voice changes/stridor/larynx 2 (33) 2 (33) 1 (17) 5 (7)
Dermatology/skin
Alopecia 1 (4) 1 (17) 2 (3)
CTC grade 3
a
Any category
Any event 1 (4) 3 (50) 2 (33) 4 (67) 3 (50) 5 (71) 18 (25)
Cardiovascular
Hypertension 1 (4) 3 (50) 2 (33) 3 (50) 2 (33) 5 (71) 16 (23)
Gastrointestinal
Dehydration 1 (17) 1 (1)
Diarrhoea, patients without colostomy 1 (17) 1 (17) 2 (29) 4 (6)
Diarrhoea, patients with colostomy 1 (17) 1 (1)
Pain
Abdominal pain or cramping 1 (17) 1 (14) 2 (3)
Dermatology/skin
Hand–foot skin reaction 1 (17) 1 (1)
Rash/desquamation 1 (17) 1 (1)
BID¼two times daily; NCI CTC¼National Cancer Institute Common Toxicity Criteria.
aThere were no study drug-related adverse events of CTC grades 4 or 5 reported in
this study.
Table 3 Geometric mean (%CV) day 14 telatinib and BAY 60–8246 pharmacokinetic parameters after oral administration of telatinib
Telatinib
Dose 75mg BID 150mg BID 300mg BID 600mg BID 900mg BID 1200mg BID 1500mg BID
n 46 6 1 1 1 2 6 1 2
Mesylate tablet 25mg 25mg 25mg 150mg 150mg 150mg 150mg
Cmax (mgl
 1) 0.212 (140%) 0.219 (80%) 0.389 (153%) 0.810 (87%) 1.275 (57%) 1.144 (40%) 0.964 (83%)
tmax (h)
a 2.1 (2.0–3.1) 3.0 (0.52–5.5) 1.5 (0–8.5) 2.1 (1.0–4.2) 2.0 (0.5–8.1) 2.5 (1–4.3) 2.5 (0.6–6.0)
AUC0–tn (mghl
 1) 1.38 (150%) 1.75 (84%) 1.92 (142%) 5.43 (68%) 7.41 (51%) 7.10 (31%) 6.17 (80%)
AUC0–12 (mghl
 1) 1.39 (146%) 1.73 (81%) 2.86 (176%)
b 5.43 (68%) 7.30 (52%) 7.26 (31%) 6.29 (84%)
t1/2 (h) 7.4 (33%) 10.9 (66%)
w 8.0 (58%)
b 8.7 (46%) 5.6 (62%)
b 5.6 (100%) 6.6 (65%)
BAY 60–8246
Cmax (mgl
 1) 0.02 (202%) 0.018 (89%) 0.021 (133%) 0.084 (140%) 0.216 (74%) 0.226 (87%) 0.102 (147%)
tmax (h)
a 3.0 (0.5–6.0) 2.5 (1.0–12.3) 1.5 (0–8.5) 2.1 (0.6–10) 3.7 (1.0–8.6) 4.0 (2.1–4.3) 3.5 (0.5–6.1)
AUC0–tn (mghl
 1) 0.125 (333%)
c 0.157 (74%) 0.115 (113%)
b 0.650 (128%) 1.27 (79%) 1.66 (81%) 0.74 (155%)
AUC0–12(mghl
 1) 0.153 (232%) 0.155 (72%) 0.219 (58%)
b 0.650 (128%) 1.25 (80%) 1.71 (84%) 0.76 (160%)
AUC0–12¼area under the plasma concentration versus time curve from time 0–12h; AUC0–tn¼area under the plasma concentration versus time curve from time 0 to last
data point; BID¼two times daily; Cmax¼maximum plasma concentration; %CV¼percent coefficient of variation; tmax¼time to reach maximum plasma concentration;
t1/2¼terminal half-life.
aMedian (range).
bSample size reduced by 2.
cSample size reduced by 1.
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and 150mg tablets indicated that the relative bioavailability of
the 150mg tablet formulation is less when compared with the
25mg tablet formulation. Increases in telatinib geometric mean
AUC0 tn and AUC0 12 followed a pattern similar to that described
for Cmax. Less than dose-proportional increase was observed in
the 600–1500mg BID dose range. In general, exposure was
comparable in the 900–1500mg BID dose range. These results
(and relevant biomarker results) formed the basis for choosing
900mg BID as the recommended phase II dose for telatinib. The
geometric mean half-life at the 900mg BID dose range was 5.6h
thus supporting the BID-dosing regimen.
After oral administration of telatinib, maximum concentrations
of the metabolite (BAY 60-8246) were observed approximately
around the same time as the parent compound or shortly
thereafter. Plasma concentrations of BAY 60-8246 were generally
lower when compared with telatinib plasma concentrations. At the
recommended phase II dose of 900mg BID, geometric mean Cmax
and AUC0 12 values of the metabolite were less than 20% of the
corresponding geometric mean Cmax and AUC0 12 values of the
parent compound. Less than dose-proportional increase observed
with the parent compound was also observed with the metabolite.
These results and the results of the mass balance study conducted
in healthy subjects (data not shown) indicate that BAY 60-8246 is
of minor importance in humans.
Pharmacodynamics
To assess the biological activity of telatinib, plasma concentration
analyses for the angiogenic markers VEGF, sVEGFR-2, bFGF,
PDGF and IL-6 were performed at baseline and during the course
of the study. Furthermore, DCE-MRI measurements were done at
baseline, on days 2 and 14 of cycle 1 and on day 14 of cycles 2 and
3. Evaluable DCE-MRI results were available for a subgroup of
patients treated at dose levels of 300mg BID or higher.
VEGF plasma levels showed a dose-dependent short-term
increase within 8h after the first telatinib administration. VEGF
levels increased also comparing day 21 to baseline. sVEGFR-2
levels showed a dose-dependent decrease over the course of the
study. In addition, a decrease in the iAUC60 for the gadolinium
curve as measured by DCE-MRI was observed.
The analysis of telatinib AUC0 12 on day 14 of cycle 1 vs the
ratio of gadolinium iAUC60 on day 14 of cycle 1 to iAUC60 at
baseline is shown in Figure 2A. In general, the gadolinium iAUC60
ratio decreased with increasing telatinib AUC0 12 although a
statistically significant correlation between telatinib exposure and
the pharmacodynamic effect as measured by DCE-MRI was not
observed (regression r
2¼0.0625; Pearson correlation coefficient
r¼ 0.250; test for no correlation, H0: r¼0, P¼0.10). Substantial
decreases in the gadolinium iAUC60 ratio were observed at total
daily doses of X600mg telatinib corresponding to telatinib
AUC0 12 values of about 4mghl
 1.
The analysis of telatinib AUC0 12 on day 14 of cycle 1 vs the
ratio of sVEGFR-2 in plasma on day 14 of cycle 1 to sVEGFR-2 at
baseline is shown in Figure 2B. The ratio of sVEGFR-2 in plasma
decreased with increasing telatinib AUC0 12, that is, essentially in
an exposure-dependent manner (regression r
2¼0.2973; Pearson
correlation coefficient r¼ 0.545; test for no correlation, H0:
r¼0, P¼0.0001).
To correlate biomarker changes to the clinical outcome, the
patients were categorised into those who had a progression-free
survival of o3 months, 3 up to 6 months, or 46 months. The
relative changes between cycle 1, day 14 and baseline were
calculated for VEGF, sVEGFR-2, bFGF, IL-8, tumour blood flow
and tumour vessel permeability as measured by DCE-MRI and
diastolic blood pressure (Figure 2C). Changes from baseline were
observed for plasma VEGF and sVEGFR-2 levels, the decrease in
tumour blood flow and permeability and also for the increase in
diastolic blood pressure. The bFGF and IL-8 plasma levels showed
no relevant changes after 14 days of multiple dosing with telatinib.
The changes in VEGF and sVEGFR-2 plasma levels, the decrease in
tumour blood flow and permeability and the increase in diastolic
blood pressure were not predictive for the clinical outcome; there
were no statistically significant differences in the change of
biomarkers for patients who reached a progression-free survival of
43 months compared with those who stopped treatment during
the first 3 months due to progressive disease.
Efficacy
Table 4 summarises the best tumour responses according to
RECIST, study duration and medication days on telatinib by
tumour type. Seventy-one patients were assessable for tumour
response. Patients with renal cell carcinoma (RCC, n¼12) showed
the most promising preliminary antitumour activity: two of them
reached a partial response, and the median treatment duration for
patients with RCC was 164 days compared with 89 days in the
overall study population.
DISCUSSION
Telatinib is safe and well tolerated up to doses of 1500mg BID
continuous dosing. The most frequent study drug-related adverse
events were hypertension and gastrointestinal toxicities such as
anorexia and diarrhoea. The treatment with telatinib had to be
dose reduced or discontinued permanently in only nine out of 71
patients due to drug-related averse events. At the highest dose level
administered in this study, 1500mg BID continuous dosing, none
of the six patients experienced a DLT within the first 21 days of
treatment, whereas at 1500mg BID noncontinuous dosing, one out
of six patients experienced a DLT, that is, grade 3 hypertension
refractory to standard treatment. The MTD was not reached in this
study.
The safety profile of telatinib is comparable to other small-
molecule VEGFR-inhibiting compounds. Hypertension as a
common class toxicity phenomenon was clinically well manageable
in most of the patients with a standard antihypertensive treatment.
Recently, Steeghs et al (2008) reported that small vessel rarefaction
may be one of the underlying haemodynamic mechanisms causing
hypertension. The average increase in diastolic blood pressure in
our study was comparable to those reported results.
In our study, diarrhoea led to dose reductions in three patients.
The occurrence of gastrointestinal toxicities is also known for
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Figure 1 Geometric mean telatinib plasma concentration vs time profiles
on day 14 of cycle 1.
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sother VEGF-inhibiting compounds (Escudier et al, 2007; Motzer
et al, 2007). The variability of pharmacokinetic parameters was
significant. Geometric mean exposure to telatinib increased in a
less than dose-proportional manner up to 1500mg BID. In general,
exposure was similar in the 900–1500mg BID dose range. Thus
further increase in dose did not result in a further increase in drug
exposure. The short half-life of 6.6–10.9h was the reason for BID
administration of telatinib.
The biomarkers assessed in this study demonstrated the
biological activity of telatinib. The angiogenic factors VEGF and
sVEGFR-2 showed effects known from other VEGF-inhibiting
compounds. Increases in VEGF and decreases in sVEGFR-2 were
dose-dependent and correlated to telatinib exposure. The DCE-
MRI parameters Ktrans and iAUC60 showed a proof of mechanism
for telatinib. However, there was no correlation between the
clinical outcome and the biomarker activity. This might be due to
the heterogeneous study population and the various dose levels
used in this study.
The safety profile of telatinib was acceptable and a toxic dose
level with two out of six or more DLTs at one dose level was not
reached in this study even at the highest dose of 1500mg BID
continuously administered. A further dose escalation was not
Table 4 Best response by tumour type and overall response according to RECIST
Primary tumour site N
Study duration (days) Medication (days) Best response Stabilisation (months)
Median Range Median Range PR SD PD clin PD meas NA o6 46 412
Colorectal 25 96 21–618 79 16–497 17 1 6 23 1 1
RCC 12 164 17–612 161 14–525 2 7 1 1 10 2
HCC 9 81 15–634 65 14–633 5 4 8 1
NSCLC 4 116 57–197 106 56–160 3 1 4
Pancreatic 4 50 15–107 43 14–105 2 2 4
Other 17 83 6–389 77 5–387 10 1 4 1 13 3
Total 71 89 6–634 79 5–633 2 42 9 14 1 62 5 3
HCC¼hepatocellular carcinoma; NA¼not assessable for response; NSCLC¼non-small-cell lung cancer; PD clin¼progressive disease, clinical judgement; PD
meas¼progressive disease, measurement proven; PR¼partial response; RCC¼renal cell carcinoma; RECIST¼Response Evaluation Criteria in Solid Tumours; SD¼stable
disease.
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sfeasible due to the number of tablets to be taken at these high dose
levels and the pharmacokinetic data showed that an exposure
plateau was reached at dose levels of 900mg BID or higher. In
concordance with the pharmacokinetic exposure, the pharmaco-
dynamic data revealed no additional effects beyond the 900mg BID
dose level. Taking the tolerability, pharmacokinetic and biomarker
data into consideration, the recommended phase II dose level for
single-agent telatinib is 900mg BID administered continuously.
The treatment with telatinib showed anticancer effects in two
patients with RCC who reached a partial remission. RCC is one of
the tumour types most sensitive to VEGF-inhibiting therapeutics
(Escudier et al, 2007; Motzer et al, 2007).
In conclusion, telatinib is an orally available small-molecule
inhibitor of VEGFR-2/-3 and PDGFR-b tyrosine kinases with a
favourable safety profile in patients with refractory advanced solid
tumours. The observed antitumour activity and pharmacodynamic
results warrant further evaluation of telatinib in patients with
advanced cancer. The recommended phase II dose of telatinib is
900mg BID as continuous dosing based on pharmacokinetic data,
the toxicity profile and the biomarker evaluations.
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